Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of...
Saved in:
| Published in | Lancet neurology Vol. 16; no. 7; pp. 552 - 563 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.07.2017
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases. |
|---|---|
| AbstractList | Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases. Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases.Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases. Summary Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. These criteria also include definitions for variant PSP syndromes with different patterns of movement, language, or behavioural features than have been conclusively associated with PSP pathology. Data from new diagnostic biomarkers can be combined with the clinical features of disease to increase the specificity of the new criteria for underlying PSP pathology. Because PSP is associated with tau protein abnormalities, there is growing interest in clinical trials of new tau-directed therapies. These therapies are hypothesised to have disease-modifying effects by reducing the concentration of toxic forms of tau in the brain or by compensating for loss of tau function. Since tau pathology is also central to Alzheimer's disease and chronic traumatic encephalopathy, a successful tau therapeutic for PSP might inform treatment of other neurodegenerative diseases. |
| Author | Lang, Anthony E Höglinger, Günter U Boxer, Adam L Yu, Jin-Tai Golbe, Lawrence I Litvan, Irene |
| Author_xml | – sequence: 1 givenname: Adam L surname: Boxer fullname: Boxer, Adam L email: adam.boxer@ucsf.edu organization: Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, USA – sequence: 2 givenname: Jin-Tai surname: Yu fullname: Yu, Jin-Tai organization: Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China – sequence: 3 givenname: Lawrence I surname: Golbe fullname: Golbe, Lawrence I organization: Department of Neurology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA – sequence: 4 givenname: Irene surname: Litvan fullname: Litvan, Irene organization: Department of Neurology, University of California, San Diego, CA, USA – sequence: 5 givenname: Anthony E surname: Lang fullname: Lang, Anthony E organization: Department of Neurology, University of Toronto, Toronto, ON, Canada – sequence: 6 givenname: Günter U surname: Höglinger fullname: Höglinger, Günter U organization: Department of Neurology, Technical University of Munich, Munich, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28653647$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkV1rFDEUhoNU7If-BCXgTQudmmQzk4xiSylahYIX6nVIMmfadGeTMZnZsv_ezO5WYUHqTRLCc56cnPcQ7fngAaHXlJxRQqt33ykXvOCcsWMqTmaElqKonqGD7XVV7v05M7aPDlO6J4RRLukLtM9kVc4qLg7Q_LJZam8hYedxH8NthJTcEnAa-6j9aDvQEfe6S6v32MMDbpy-9SENzmIb3QDR6VNsXFjoOIeYTrH2DR7uIOoexonSfdZqewfpJXreZhG82u5H6OfnTz-uvhQ3366_Xl3eFLbk9VC0pRS8roUkDGRJAKpZ3RpDdUuMEJqDtkaUjFPLjKzbupayqQRnEgw1RlazI3S88eaHf42QBrVwyULXaQ9hTIrWlLM6rySjb3fQ-zBGn7ubKEoll5Jl6s2WGs0CGtVHl7-7Uo9jzMCHDWBjSClCq6wb9OCCH6J2naJETaGpdWhqSkRRodahqanfcqf68YGn6i42dZCHuXQQVbIOcpiNi2AH1QT3pOF8x2A7553V3RxWkP7OQiWmyEYyOahYGybBx38L_qOB3-RX1rg |
| CitedBy_id | crossref_primary_10_1007_s10072_021_05601_8 crossref_primary_10_1007_s00415_019_09566_9 crossref_primary_10_3389_fnins_2024_1345225 crossref_primary_10_1001_jamaneurol_2019_0250 crossref_primary_10_1007_s10072_019_04010_2 crossref_primary_10_3390_brainsci12070949 crossref_primary_10_1007_s00415_024_12551_6 crossref_primary_10_1016_j_jns_2018_06_005 crossref_primary_10_1002_mdc3_12940 crossref_primary_10_1371_journal_pone_0223113 crossref_primary_10_1016_j_neuroscience_2019_10_001 crossref_primary_10_4103_aian_aian_703_22 crossref_primary_10_1002_mds_27621 crossref_primary_10_1097_WCO_0000000000000502 crossref_primary_10_1007_s10072_022_06296_1 crossref_primary_10_1016_j_trci_2019_09_005 crossref_primary_10_1038_s41392_023_01588_0 crossref_primary_10_1038_s41467_024_55442_0 crossref_primary_10_1002_mds_28038 crossref_primary_10_3390_brainsci10060399 crossref_primary_10_1007_s43657_022_00079_6 crossref_primary_10_1016_j_rcp_2023_10_003 crossref_primary_10_1016_j_parkreldis_2024_107226 crossref_primary_10_1007_s00702_025_02890_7 crossref_primary_10_1016_j_gaitpost_2020_02_007 crossref_primary_10_1016_j_nbd_2020_105120 crossref_primary_10_1016_j_parkreldis_2018_10_006 crossref_primary_10_1016_j_parkreldis_2020_08_021 crossref_primary_10_1111_jnp_12232 crossref_primary_10_7759_cureus_47313 crossref_primary_10_1038_s41380_018_0071_z crossref_primary_10_1007_s00428_024_03781_0 crossref_primary_10_1212_WNL_0000000000007889 crossref_primary_10_1016_S1474_4422_19_30139_5 crossref_primary_10_1093_brain_awab130 crossref_primary_10_1016_j_jns_2020_117293 crossref_primary_10_1177_17562864241267300 crossref_primary_10_1016_j_amjmed_2019_04_014 crossref_primary_10_1093_arclin_acad081 crossref_primary_10_1007_s00391_022_02077_9 crossref_primary_10_1097_RLU_0000000000005062 crossref_primary_10_3390_brainsci10110858 crossref_primary_10_1002_mds_27408 crossref_primary_10_1016_j_jns_2022_120536 crossref_primary_10_1016_j_jns_2023_120614 crossref_primary_10_3389_fnagi_2020_00126 crossref_primary_10_1002_mdc3_13334 crossref_primary_10_1080_14728214_2019_1609450 crossref_primary_10_1007_s00115_018_0584_3 crossref_primary_10_1007_s00415_021_10936_5 crossref_primary_10_1038_s41591_021_01455_x crossref_primary_10_1111_neup_12890 crossref_primary_10_1007_s00415_023_11892_y crossref_primary_10_1093_braincomms_fcaf022 crossref_primary_10_1007_s00259_024_06923_3 crossref_primary_10_1016_j_parkreldis_2021_11_020 crossref_primary_10_1038_s41531_022_00304_z crossref_primary_10_1016_j_cpet_2020_12_002 crossref_primary_10_1267_ahc_21_00019 crossref_primary_10_1097_CM9_0000000000000836 crossref_primary_10_3390_brainsci14090859 crossref_primary_10_3389_fnagi_2021_720634 crossref_primary_10_3390_cells9010002 crossref_primary_10_1002_mds_27877 crossref_primary_10_1002_mdc3_14315 crossref_primary_10_1002_mds_27992 crossref_primary_10_1016_j_nbd_2022_105819 crossref_primary_10_1002_ana_26187 crossref_primary_10_1002_mdc3_14313 crossref_primary_10_5692_clinicalneurol_cn_001920 crossref_primary_10_1002_mds_27872 crossref_primary_10_3390_ijms21238948 crossref_primary_10_1007_s00415_024_12391_4 crossref_primary_10_4103_0028_3886_333499 crossref_primary_10_3389_fnagi_2023_1229491 crossref_primary_10_1186_s40478_020_01035_z crossref_primary_10_1016_j_nrl_2023_06_010 crossref_primary_10_1016_j_neuroimage_2025_121001 crossref_primary_10_1007_s12031_017_0983_0 crossref_primary_10_1002_mds_27788 crossref_primary_10_3389_fnagi_2021_625874 crossref_primary_10_1002_mds_28992 crossref_primary_10_1002_INMD_20240013 crossref_primary_10_1002_mdc3_13435 crossref_primary_10_1016_j_parkreldis_2019_07_010 crossref_primary_10_1007_s00415_021_10703_6 crossref_primary_10_1186_s13195_023_01321_7 crossref_primary_10_1016_j_parkreldis_2017_10_020 crossref_primary_10_1016_j_parkreldis_2018_02_025 crossref_primary_10_1212_WNL_0000000000012639 crossref_primary_10_3390_cells8020151 crossref_primary_10_3988_jcn_2022_18_3_259 crossref_primary_10_1007_s00415_019_09324_x crossref_primary_10_1212_WNL_0000000000200967 crossref_primary_10_1016_S1474_4422_19_30161_9 crossref_primary_10_1111_jcmm_13545 crossref_primary_10_1016_j_nicl_2019_101899 crossref_primary_10_1016_j_parkreldis_2018_02_020 crossref_primary_10_1016_j_nbd_2024_106493 crossref_primary_10_1016_j_jalz_2018_07_218 crossref_primary_10_1007_s15016_018_6475_9 crossref_primary_10_1016_j_dadm_2019_01_001 crossref_primary_10_1186_s40658_024_00712_5 crossref_primary_10_1038_s41598_019_42565_4 crossref_primary_10_1042_BSR20203672 crossref_primary_10_1111_ane_13372 crossref_primary_10_3389_fnagi_2021_635896 crossref_primary_10_1001_jamaneurol_2024_3162 crossref_primary_10_1371_journal_pone_0234265 crossref_primary_10_1002_mds_30027 crossref_primary_10_1016_j_isci_2023_107426 crossref_primary_10_3390_jcm12206671 crossref_primary_10_1016_j_neurol_2022_03_010 crossref_primary_10_1007_s00415_021_10511_y crossref_primary_10_1016_j_parkreldis_2023_105313 crossref_primary_10_3390_brainsci11070879 crossref_primary_10_1097_WCO_0000000000000521 crossref_primary_10_1001_jamanetworkopen_2022_9588 crossref_primary_10_3390_biomedicines11082091 crossref_primary_10_1016_j_parkreldis_2024_107251 crossref_primary_10_1016_j_parkreldis_2019_07_009 crossref_primary_10_1016_j_parkreldis_2025_107301 crossref_primary_10_1093_braincomms_fcaf066 crossref_primary_10_1002_mdc3_12582 crossref_primary_10_1016_j_eclinm_2023_101888 crossref_primary_10_1093_cercor_bhac041 crossref_primary_10_3233_JAD_200589 crossref_primary_10_1038_nrneurol_2018_23 crossref_primary_10_1007_s10072_023_06766_0 crossref_primary_10_3389_fneur_2024_1372507 crossref_primary_10_3390_biom14101213 crossref_primary_10_1007_s00415_021_10522_9 crossref_primary_10_1126_sciadv_abm5029 crossref_primary_10_1159_000503864 crossref_primary_10_1007_s00702_023_02591_z crossref_primary_10_1002_mds_29299 crossref_primary_10_1007_s00415_025_12983_8 crossref_primary_10_1016_j_intimp_2022_109445 crossref_primary_10_1016_j_parkreldis_2019_07_003 crossref_primary_10_1038_s41582_021_00541_5 crossref_primary_10_1080_13803395_2019_1572073 crossref_primary_10_1007_s40263_018_0551_3 crossref_primary_10_1007_s00062_018_0727_8 crossref_primary_10_1016_j_parkreldis_2018_08_025 crossref_primary_10_1590_0004_282x_anp_2022_s134 crossref_primary_10_1002_mds_29769 crossref_primary_10_1038_s41598_019_56930_w crossref_primary_10_1002_alz_12453 crossref_primary_10_36290_neu_2021_034 crossref_primary_10_1007_s00415_024_12419_9 crossref_primary_10_1007_s10072_020_04305_9 crossref_primary_10_1080_13854046_2019_1670865 crossref_primary_10_1371_journal_pone_0279315 crossref_primary_10_3390_brainsci12091126 crossref_primary_10_1007_s00702_025_02904_4 crossref_primary_10_3390_diseases13020039 crossref_primary_10_3390_ijms25158243 crossref_primary_10_1002_mds_28672 crossref_primary_10_1007_s40120_024_00614_9 crossref_primary_10_1016_j_nicl_2019_102091 crossref_primary_10_1016_j_parkreldis_2023_105296 crossref_primary_10_1007_s00415_021_10939_2 crossref_primary_10_3389_fneur_2021_648548 crossref_primary_10_1016_j_jns_2019_116443 crossref_primary_10_1001_jamanetworkopen_2021_1290 crossref_primary_10_1177_1877718X241291996 crossref_primary_10_1212_WNL_0000000000005069 crossref_primary_10_1016_j_nicl_2020_102416 crossref_primary_10_1002_mdc3_14182 crossref_primary_10_3390_ijms232314554 crossref_primary_10_1007_s00115_018_0590_5 crossref_primary_10_1007_s00702_018_1893_1 crossref_primary_10_1177_10738584211036693 crossref_primary_10_3389_fneur_2018_00319 crossref_primary_10_1093_brain_awz122 crossref_primary_10_1002_mdc3_12676 crossref_primary_10_1371_journal_pone_0223621 crossref_primary_10_1097_WCO_0000000000000578 crossref_primary_10_1016_j_praneu_2019_02_001 crossref_primary_10_3390_cells12242776 crossref_primary_10_1136_jnnp_2018_318603 crossref_primary_10_1016_j_parkreldis_2019_02_014 crossref_primary_10_1007_s00259_024_06954_w crossref_primary_10_1007_s00415_019_09382_1 crossref_primary_10_1016_j_brainresbull_2024_111046 crossref_primary_10_1038_s41398_017_0049_7 crossref_primary_10_30629_26587947_2023_28_1_5_12 crossref_primary_10_1016_j_jocn_2020_06_008 crossref_primary_10_1111_ejn_15496 crossref_primary_10_1371_journal_pone_0283941 crossref_primary_10_3233_JPD_202302 crossref_primary_10_1002_pcn5_178 crossref_primary_10_1016_j_jalz_2019_06_4956 crossref_primary_10_17116_jnevro202012010222 crossref_primary_10_1212_CON_0000000000001134 crossref_primary_10_1016_j_dadm_2019_01_011 crossref_primary_10_1111_neup_12805 crossref_primary_10_2967_jnumed_124_268754 crossref_primary_10_3389_fneur_2021_571800 crossref_primary_10_1136_jnnp_2017_317443 crossref_primary_10_1007_s10072_019_03944_x crossref_primary_10_1007_s00401_024_02823_w crossref_primary_10_1093_omcr_omaa073 crossref_primary_10_14802_jmd_19061 crossref_primary_10_1016_j_prdoa_2022_100155 crossref_primary_10_3389_fneur_2021_637176 crossref_primary_10_1016_j_expneurol_2022_114241 crossref_primary_10_1016_j_cortex_2020_12_019 crossref_primary_10_1097_WCO_0000000000000792 crossref_primary_10_1002_mds_29774 crossref_primary_10_1016_j_cortex_2022_07_015 crossref_primary_10_1111_nan_12692 crossref_primary_10_1016_j_bcp_2022_114979 crossref_primary_10_1002_mdc3_13987 crossref_primary_10_3892_etm_2022_11411 crossref_primary_10_1016_j_parkreldis_2018_07_016 crossref_primary_10_1016_j_brs_2019_05_017 crossref_primary_10_3390_medicina59101696 crossref_primary_10_1007_s00415_018_9038_x crossref_primary_10_3233_ADR_210309 crossref_primary_10_3389_fneur_2018_00347 crossref_primary_10_3389_fneur_2021_664796 crossref_primary_10_3389_fnagi_2022_804385 crossref_primary_10_1007_s00702_025_02902_6 crossref_primary_10_1016_j_jad_2020_07_127 crossref_primary_10_1007_s00259_022_06104_0 crossref_primary_10_1186_s12014_024_09507_3 crossref_primary_10_1007_s13311_020_00888_5 crossref_primary_10_1016_S1474_4422_21_00341_0 crossref_primary_10_1002_jcp_30853 crossref_primary_10_3233_JAD_201139 crossref_primary_10_3389_fneur_2020_580732 crossref_primary_10_1016_j_parkreldis_2020_01_019 crossref_primary_10_3233_JAD_200287 crossref_primary_10_3390_app14188368 crossref_primary_10_1002_brb3_2827 crossref_primary_10_1016_j_jns_2018_02_019 crossref_primary_10_1093_braincomms_fcab206 crossref_primary_10_1002_mdc3_12879 crossref_primary_10_1007_s00401_022_02479_4 crossref_primary_10_1212_WNL_0000000000004859 crossref_primary_10_1038_s41467_018_05325_y crossref_primary_10_1016_j_neurol_2018_07_001 crossref_primary_10_1111_nan_12757 crossref_primary_10_1093_braincomms_fcac098 crossref_primary_10_1111_ane_13653 crossref_primary_10_1007_s00115_021_01210_0 crossref_primary_10_3390_ijms25136882 crossref_primary_10_1002_hbm_24044 crossref_primary_10_1007_s42451_023_00590_8 crossref_primary_10_1111_cns_14901 crossref_primary_10_31083_j_jin2004108 crossref_primary_10_1016_j_ebiom_2023_104835 crossref_primary_10_1016_j_neulet_2021_135975 crossref_primary_10_1186_s13024_018_0267_3 crossref_primary_10_1007_s10072_025_07996_0 crossref_primary_10_3390_biom10040571 crossref_primary_10_1001_jamaneurol_2020_2526 crossref_primary_10_1080_14656566_2024_2345734 crossref_primary_10_3389_fneur_2020_599384 crossref_primary_10_1016_S1634_7072_24_49601_3 crossref_primary_10_1002_mds_27964 crossref_primary_10_1016_j_parkreldis_2018_03_014 crossref_primary_10_1186_s12883_019_1270_1 crossref_primary_10_1089_hum_2021_012 crossref_primary_10_1080_13543784_2018_1460356 crossref_primary_10_3389_fneur_2022_821570 crossref_primary_10_1007_s10072_019_04208_4 crossref_primary_10_1007_s00259_021_05391_3 crossref_primary_10_1016_S1474_4422_20_30489_0 crossref_primary_10_1016_j_neuropsychologia_2019_05_003 crossref_primary_10_1007_s00415_023_12009_1 crossref_primary_10_1093_scan_nsaa060 crossref_primary_10_1007_s00702_023_02621_w crossref_primary_10_1016_j_parkreldis_2021_03_002 crossref_primary_10_1053_j_semnuclmed_2020_12_003 crossref_primary_10_1097_RLU_0000000000002949 crossref_primary_10_3389_fneur_2021_694872 crossref_primary_10_1212_WNL_0000000000008197 crossref_primary_10_1016_j_nicl_2019_102009 crossref_primary_10_3389_fnagi_2022_851788 crossref_primary_10_1016_j_cca_2024_118784 crossref_primary_10_1016_j_neurop_2022_05_001 crossref_primary_10_31083_j_fbl2801021 crossref_primary_10_1002_mds_28364 crossref_primary_10_1007_s00259_018_4027_y crossref_primary_10_3233_JPD_223553 |
| Cites_doi | 10.1002/mds.22023 10.1212/WNL.0000000000003680 10.1212/WNL.0000000000001997 10.1371/journal.pone.0170927 10.1016/S1474-4422(09)70042-0 10.1001/archneurol.2012.1654 10.1272/jnms.82.266 10.1016/j.neurobiolaging.2012.02.002 10.1016/S1474-4422(10)70002-8 10.1016/S0140-6736(16)31275-2 10.1001/archneurol.2011.1021 10.1038/nn.4132 10.1002/mds.26512 10.1212/WNL.47.1.1 10.1073/pnas.1301175110 10.1016/j.parkreldis.2014.10.028 10.1212/WNL.0000000000003125 10.1523/JNEUROSCI.2336-15.2016 10.1016/j.neuron.2013.12.003 10.1093/hmg/dds161 10.1002/ana.23844 10.1002/mds.22977 10.1212/WNL.0b013e318292a2d2 10.1016/j.molmed.2015.03.003 10.1016/j.neurobiolaging.2014.09.007 10.1212/WNL.0b013e3181a92bcc 10.1002/mds.26499 10.1016/j.neuron.2016.05.018 10.1093/brain/awr179 10.1212/WNL.0000000000003305 10.1212/WNL.0b013e31822e55d0 10.1002/mds.25824 10.3389/fneur.2010.00147 10.1038/ng.859 10.1523/JNEUROSCI.0834-10.2010 10.1093/brain/awn291 10.1212/WNL.0000000000002638 10.1002/mds.22583 10.1055/s-0034-1381739 10.1002/mds.26813 10.1136/jnnp-2014-309562 10.1007/s00401-016-1665-7 10.1093/brain/aws038 10.1097/NEN.0000000000000224 10.1038/nature14658 10.1097/00005072-199601000-00010 10.1002/ana.24517 10.1016/S1474-4422(14)70088-2 10.1002/mds.26054 10.1002/ana.24052 10.1002/mds.26431 10.1111/ene.12212 10.1080/13554794.2011.627345 10.1097/NEN.0000000000000046 10.1016/j.jalz.2016.06.006 10.1016/j.neurobiolaging.2006.09.019 10.1001/archneur.1964.00460160003001 10.1016/j.sleep.2016.05.002 10.1016/j.neuron.2014.04.047 10.14802/jmd.15060 10.1371/journal.pone.0157218 10.1093/brain/awv361 10.1093/brain/awu223 10.1007/s00702-013-1072-3 10.1007/s00259-015-3231-2 10.1007/s00401-013-1157-y 10.1016/j.neuron.2010.08.023 10.1002/brb3.557 10.1007/s00415-016-8278-x 10.1002/ana.24885 10.1002/mds.24968 10.1111/nan.12037 10.1126/scitranslmed.aag0481 10.1093/brain/awn317 10.1016/j.neuron.2016.04.042 10.1212/WNL.0000000000002985 10.1097/WCO.0b013e32833be924 10.1212/NXI.0000000000000266 10.1212/WNL.0b013e31827f0fd1 10.1002/mds.26844 10.1016/j.neuron.2015.08.020 10.1002/acn3.290 10.1007/s11940-016-0422-5 10.1016/j.neuron.2013.07.046 10.1152/jn.00062.2014 10.1001/jamaneurol.2016.0412 10.1038/nm.3951 10.1007/s00415-014-7256-4 10.1038/nm.3569 10.1002/acn3.176 10.1002/mds.26987 10.1136/jnnp-2016-315192 10.1136/jnnp-2014-308004 10.1016/j.parkreldis.2014.02.012 10.1002/mds.26834 10.1093/brain/awq123 10.1212/WNL.0b013e31821103e6 10.1002/mds.25327 10.1126/science.1194653 10.1038/nchembio.797 |
| ContentType | Journal Article |
| Copyright | 2017 Elsevier Ltd Elsevier Ltd Copyright © 2017 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jul 1, 2017 |
| Copyright_xml | – notice: 2017 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2017 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jul 1, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1016/S1474-4422(17)30157-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-4465 |
| EndPage | 563 |
| ExternalDocumentID | 28653647 10_1016_S1474_4422_17_30157_6 S1474442217301576 1_s2_0_S1474442217301576 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: T35 HL007491 – fundername: NIA NIH HHS grantid: R01 AG038791 – fundername: NINDS NIH HHS grantid: U54 NS092089 – fundername: NINDS NIH HHS grantid: U01 NS086659 – fundername: NIA NIH HHS grantid: P50 AG005131 – fundername: NIA NIH HHS grantid: P01 AG019724 |
| GroupedDBID | --- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PUEGO ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AADPK ABLVK ABYKQ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c549t-f5874997802e850ee639fbb1af0b77a4eacb75241c2b89f9988d67428eb1bb863 |
| IEDL.DBID | 7X7 |
| ISSN | 1474-4422 1474-4465 |
| IngestDate | Fri Jul 11 16:03:29 EDT 2025 Wed Aug 13 09:25:31 EDT 2025 Mon Jul 21 05:53:20 EDT 2025 Thu Apr 24 22:58:54 EDT 2025 Tue Jul 01 02:24:38 EDT 2025 Fri Feb 23 02:29:00 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Aug 26 16:34:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | Copyright © 2017 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c549t-f5874997802e850ee639fbb1af0b77a4eacb75241c2b89f9988d67428eb1bb863 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/5802400 |
| PMID | 28653647 |
| PQID | 1911184882 |
| PQPubID | 26255 |
| PageCount | 12 |
| ParticipantIDs | proquest_miscellaneous_1914291910 proquest_journals_1911184882 pubmed_primary_28653647 crossref_citationtrail_10_1016_S1474_4422_17_30157_6 crossref_primary_10_1016_S1474_4422_17_30157_6 elsevier_sciencedirect_doi_10_1016_S1474_4422_17_30157_6 elsevier_clinicalkeyesjournals_1_s2_0_S1474442217301576 elsevier_clinicalkey_doi_10_1016_S1474_4422_17_30157_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-07-01 |
| PublicationDateYYYYMMDD | 2017-07-01 |
| PublicationDate_xml | – month: 07 year: 2017 text: 2017-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Lancet neurology |
| PublicationTitleAlternate | Lancet Neurol |
| PublicationYear | 2017 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Williams, Lees (bib17) 2010; 25 Marquié, Normandin, Vanderburg (bib62) 2015; 78 Min, Chen, Tracy (bib49) 2015; 21 Litvan, Lees, Cunningham (bib9) 2016; 31 Ling, O'Sullivan, Holton (bib19) 2010; 133 Williams, Lees (bib1) 2009; 8 Yuzwa, Shan, Macauley (bib88) 2012; 8 Bhaskar, Konerth, Kokiko-Cochran, Cardona, Ransohoff, Lamb (bib100) 2010; 68 Yoshida, Hata, Kinoshita, Takashima, Tanaka, Nishida (bib7) 2017; 133 Hoglinger, Respondek, Stamelou (bib10) 2017 Schneider, Müller, Lauda (bib76) 2014; 121 Bruch, Kurz, Vasiljevic, Nicolino, Arzberger, Höglinger (bib46) 2015; 74 Smith, Schain, Nilsson (bib65) 2017; 32 Sanders, Kaufman, DeVos (bib38) 2014; 82 Litvan, Hauw, Bartko (bib24) 1996; 55 Hampton, Webber, Bilican, Goedert, Spillantini, Chandran (bib102) 2010; 30 Ling (bib27) 2016; 9 Apetauerova, Scala, Hamill (bib83) 2016; 3 Vossel, Zhang, Brodbeck (bib98) 2010; 330 Schoch, DeVos, Miller (bib44) 2016; 90 Dutt, Binney, Heuer (bib55) 2016; 87 Boxer, Lang, Grossman (bib70) 2014; 13 Rascovsky, Hodges, Knopman (bib32) 2011; 134 Hoglinger, Melhem, Dickson (bib4) 2011; 43 Donker, Boon, Azmani (bib42) 2009; 73 Quattrone, Morelli, Williams (bib54) 2016; 87 Villeda, Plambeck, Middeldorp (bib87) 2014; 20 Zhang, Walter, Ng (bib56) 2016; 11 Ling, de Silva, Massey (bib36) 2014; 40 Boxer, Garbutt, Seeley (bib29) 2012; 69 Kanazawa, Shimohata, Toyoshima (bib33) 2009; 24 Yanamandra, Kfoury, Jiang (bib95) 2013; 80 Dugger, Hentz, Adler (bib13) 2014; 73 Josephs, Duffy, Strand (bib20) 2014; 137 Kondo, Shahpasand, Mannix (bib96) 2015; 523 Scelzo, Lozano, Hamani (bib91) 2017 Tang, Poston, Eckert (bib61) 2010; 9 Hinz, Geschwind (bib40) 2016 Hall, Öhrfelt, Constantinescu (bib68) 2012; 69 Fujioka, Sanchez, Strongosky (bib43) 2015; 21 Zhao, Tseng, Heyser (bib45) 2015; 87 Hughes, Rowe, Ghosh, Carlyon, Plack, Gockel (bib66) 2014; 112 Cho, Choi, Hwang (bib63) 2017; 32 Clavaguera, Akatsu, Fraser (bib37) 2013; 110 Koga, Josephs, Ogaki (bib25) 2016; 31 Coppola, Chinnathambi, Lee (bib41) 2012; 21 Lamb, Rohrer, Lees, Morris (bib3) 2016; 18 Gardner, Boxer, Trujillo (bib39) 2013; 73 Dugger, Adler, Shill (bib34) 2014; 20 Berg, Postuma, Adler (bib12) 2015; 30 Chen, Riley, King (bib81) 2010; 1 Asai, Ikezu, Tsunoda (bib99) 2015; 18 Rojas, Karydas, Bang (bib74) 2016; 3 Burciu, Chung, Shukla (bib59) 2016; 87 Josephs, Whitwell, Dickson (bib48) 2008; 29 Steele, Richardson, Olszewski (bib2) 1964; 10 Gauthier, Feldman, Schneider (bib85) 2016; 388 Bensimon, Ludolph, Agid, Vidailhet, Payan, Leigh (bib93) 2009; 132 Bright, Hussain, Dang (bib86) 2015; 36 Zalewski, Botha, Whitwell, Lowe, Dickson, Josephs (bib60) 2014; 261 Spinelli, Mandelli, Miller (bib22) 2017; 81 Wagshal, Sankaranarayanan, Guss (bib67) 2015; 86 Khanna, Kovalevich, Lee, Trojanowski, Brunden (bib84) 2016; 12 Armstrong, Litvan, Lang (bib30) 2013; 80 Santos-Santos, Mandelli, Binney (bib21) 2016; 73 Dickson, Ahmed, Algom, Tsuboi, Josephs (bib35) 2010; 23 Pedersen, Sigurdsson (bib97) 2015; 21 Massey, Jager, Paviour (bib53) 2013; 80 Respondek, Stamelou, Kurz (bib15) 2014; 29 Massey, Micallef, Paviour (bib47) 2012; 27 Dani, Brooks, Edison (bib79) 2016; 43 Nogami, Yamazaki, Saito (bib14) 2015; 82 Clerici, Ferrazzoli, Maestri (bib82) 2017; 12 Agosta, Pievani, Svetel (bib57) 2012; 33 Walsh, Ruoff, Varbel (bib77) 2016; 22 Coyle-Gilchrist, Dick, Patterson (bib5) 2016; 86 Takigawa, Kitayama, Wada-Isoe, Kowa, Nakashima (bib6) 2016; 6 Hassan, Parisi, Josephs (bib23) 2012; 18 Yanamandra, Jiang, Mahan (bib50) 2015; 2 Scherling, Hall, Berisha (bib69) 2014; 75 Jack, Holtzman (bib11) 2013; 80 Hansson, Janelidze, Hall (bib73) 2017; 88 Stamelou, Reuss, Pilatus (bib90) 2008; 23 Ling, Massey, Lees, Brown, Day (bib78) 2012; 135 Kovacs, Milenkovic, Wöhrer (bib26) 2013; 126 Respondek, Roeber, Kretzschmar (bib16) 2013; 28 Bacioglu, Maia, Preische (bib71) 2016; 91 Whitwell, Jack, Parisi (bib51) 2013; 20 Gentry, Henderson, Arrant (bib101) 2016; 36 Litvan, Agid, Calne (bib28) 1996; 47 Owens, Josephs, Savica (bib18) 2016; 263 Bologna, Agostino, Gregori (bib75) 2009; 132 Ono, Sahara, Kumata (bib80) 2017; 140 Tsai, Boxer (bib92) 2014; 34 Magdalinou, Paterson, Schott (bib72) 2015; 86 Gorno-Tempini, Hillis, Weintraub (bib31) 2011; 76 DeVos, Miller, Schoch (bib89) 2017; 9 Morelli, Arabia, Novellino (bib52) 2011; 77 Caparros-Lefebvre, Golbe, Deramecourt (bib8) 2015; 85 Planetta, Ofori, Pasternak (bib58) 2016; 139 Whitwell, Lowe, Tosakulwong (bib64) 2017; 32 Tolosa, Litvan, Höglinger (bib94) 2014; 29 Sanders (10.1016/S1474-4422(17)30157-6_bib38) 2014; 82 Litvan (10.1016/S1474-4422(17)30157-6_bib9) 2016; 31 Gentry (10.1016/S1474-4422(17)30157-6_bib101) 2016; 36 Nogami (10.1016/S1474-4422(17)30157-6_bib14) 2015; 82 Ling (10.1016/S1474-4422(17)30157-6_bib78) 2012; 135 Zhang (10.1016/S1474-4422(17)30157-6_bib56) 2016; 11 Zalewski (10.1016/S1474-4422(17)30157-6_bib60) 2014; 261 Ling (10.1016/S1474-4422(17)30157-6_bib19) 2010; 133 Agosta (10.1016/S1474-4422(17)30157-6_bib57) 2012; 33 Pedersen (10.1016/S1474-4422(17)30157-6_bib97) 2015; 21 Owens (10.1016/S1474-4422(17)30157-6_bib18) 2016; 263 Gauthier (10.1016/S1474-4422(17)30157-6_bib85) 2016; 388 Lamb (10.1016/S1474-4422(17)30157-6_bib3) 2016; 18 Hoglinger (10.1016/S1474-4422(17)30157-6_bib4) 2011; 43 Williams (10.1016/S1474-4422(17)30157-6_bib17) 2010; 25 Hansson (10.1016/S1474-4422(17)30157-6_bib73) 2017; 88 Vossel (10.1016/S1474-4422(17)30157-6_bib98) 2010; 330 Clerici (10.1016/S1474-4422(17)30157-6_bib82) 2017; 12 Apetauerova (10.1016/S1474-4422(17)30157-6_bib83) 2016; 3 Coyle-Gilchrist (10.1016/S1474-4422(17)30157-6_bib5) 2016; 86 Walsh (10.1016/S1474-4422(17)30157-6_bib77) 2016; 22 Takigawa (10.1016/S1474-4422(17)30157-6_bib6) 2016; 6 Yanamandra (10.1016/S1474-4422(17)30157-6_bib50) 2015; 2 Koga (10.1016/S1474-4422(17)30157-6_bib25) 2016; 31 Dutt (10.1016/S1474-4422(17)30157-6_bib55) 2016; 87 Kanazawa (10.1016/S1474-4422(17)30157-6_bib33) 2009; 24 Josephs (10.1016/S1474-4422(17)30157-6_bib48) 2008; 29 Respondek (10.1016/S1474-4422(17)30157-6_bib15) 2014; 29 Rascovsky (10.1016/S1474-4422(17)30157-6_bib32) 2011; 134 Gardner (10.1016/S1474-4422(17)30157-6_bib39) 2013; 73 Rojas (10.1016/S1474-4422(17)30157-6_bib74) 2016; 3 Fujioka (10.1016/S1474-4422(17)30157-6_bib43) 2015; 21 Hampton (10.1016/S1474-4422(17)30157-6_bib102) 2010; 30 Respondek (10.1016/S1474-4422(17)30157-6_bib16) 2013; 28 Bruch (10.1016/S1474-4422(17)30157-6_bib46) 2015; 74 Villeda (10.1016/S1474-4422(17)30157-6_bib87) 2014; 20 Ling (10.1016/S1474-4422(17)30157-6_bib36) 2014; 40 Dani (10.1016/S1474-4422(17)30157-6_bib79) 2016; 43 Berg (10.1016/S1474-4422(17)30157-6_bib12) 2015; 30 Bologna (10.1016/S1474-4422(17)30157-6_bib75) 2009; 132 Caparros-Lefebvre (10.1016/S1474-4422(17)30157-6_bib8) 2015; 85 Litvan (10.1016/S1474-4422(17)30157-6_bib28) 1996; 47 Wagshal (10.1016/S1474-4422(17)30157-6_bib67) 2015; 86 Boxer (10.1016/S1474-4422(17)30157-6_bib29) 2012; 69 Armstrong (10.1016/S1474-4422(17)30157-6_bib30) 2013; 80 Schneider (10.1016/S1474-4422(17)30157-6_bib76) 2014; 121 Smith (10.1016/S1474-4422(17)30157-6_bib65) 2017; 32 Boxer (10.1016/S1474-4422(17)30157-6_bib70) 2014; 13 Marquié (10.1016/S1474-4422(17)30157-6_bib62) 2015; 78 Santos-Santos (10.1016/S1474-4422(17)30157-6_bib21) 2016; 73 Schoch (10.1016/S1474-4422(17)30157-6_bib44) 2016; 90 Chen (10.1016/S1474-4422(17)30157-6_bib81) 2010; 1 Yuzwa (10.1016/S1474-4422(17)30157-6_bib88) 2012; 8 Kondo (10.1016/S1474-4422(17)30157-6_bib96) 2015; 523 Quattrone (10.1016/S1474-4422(17)30157-6_bib54) 2016; 87 Whitwell (10.1016/S1474-4422(17)30157-6_bib64) 2017; 32 Magdalinou (10.1016/S1474-4422(17)30157-6_bib72) 2015; 86 Morelli (10.1016/S1474-4422(17)30157-6_bib52) 2011; 77 Tolosa (10.1016/S1474-4422(17)30157-6_bib94) 2014; 29 Massey (10.1016/S1474-4422(17)30157-6_bib53) 2013; 80 Yanamandra (10.1016/S1474-4422(17)30157-6_bib95) 2013; 80 Bhaskar (10.1016/S1474-4422(17)30157-6_bib100) 2010; 68 Ono (10.1016/S1474-4422(17)30157-6_bib80) 2017; 140 Khanna (10.1016/S1474-4422(17)30157-6_bib84) 2016; 12 Tsai (10.1016/S1474-4422(17)30157-6_bib92) 2014; 34 Min (10.1016/S1474-4422(17)30157-6_bib49) 2015; 21 Zhao (10.1016/S1474-4422(17)30157-6_bib45) 2015; 87 Tang (10.1016/S1474-4422(17)30157-6_bib61) 2010; 9 Dugger (10.1016/S1474-4422(17)30157-6_bib34) 2014; 20 Whitwell (10.1016/S1474-4422(17)30157-6_bib51) 2013; 20 Burciu (10.1016/S1474-4422(17)30157-6_bib59) 2016; 87 Planetta (10.1016/S1474-4422(17)30157-6_bib58) 2016; 139 Dickson (10.1016/S1474-4422(17)30157-6_bib35) 2010; 23 Massey (10.1016/S1474-4422(17)30157-6_bib47) 2012; 27 Litvan (10.1016/S1474-4422(17)30157-6_bib24) 1996; 55 Gorno-Tempini (10.1016/S1474-4422(17)30157-6_bib31) 2011; 76 Hinz (10.1016/S1474-4422(17)30157-6_bib40) 2016 Hughes (10.1016/S1474-4422(17)30157-6_bib66) 2014; 112 Stamelou (10.1016/S1474-4422(17)30157-6_bib90) 2008; 23 Cho (10.1016/S1474-4422(17)30157-6_bib63) 2017; 32 Scelzo (10.1016/S1474-4422(17)30157-6_bib91) 2017 Williams (10.1016/S1474-4422(17)30157-6_bib1) 2009; 8 Scherling (10.1016/S1474-4422(17)30157-6_bib69) 2014; 75 Hoglinger (10.1016/S1474-4422(17)30157-6_bib10) 2017 Donker (10.1016/S1474-4422(17)30157-6_bib42) 2009; 73 DeVos (10.1016/S1474-4422(17)30157-6_bib89) 2017; 9 Bensimon (10.1016/S1474-4422(17)30157-6_bib93) 2009; 132 Bright (10.1016/S1474-4422(17)30157-6_bib86) 2015; 36 Ling (10.1016/S1474-4422(17)30157-6_bib27) 2016; 9 Steele (10.1016/S1474-4422(17)30157-6_bib2) 1964; 10 Coppola (10.1016/S1474-4422(17)30157-6_bib41) 2012; 21 Bacioglu (10.1016/S1474-4422(17)30157-6_bib71) 2016; 91 Yoshida (10.1016/S1474-4422(17)30157-6_bib7) 2017; 133 Jack (10.1016/S1474-4422(17)30157-6_bib11) 2013; 80 Dugger (10.1016/S1474-4422(17)30157-6_bib13) 2014; 73 Kovacs (10.1016/S1474-4422(17)30157-6_bib26) 2013; 126 Hall (10.1016/S1474-4422(17)30157-6_bib68) 2012; 69 Josephs (10.1016/S1474-4422(17)30157-6_bib20) 2014; 137 Hassan (10.1016/S1474-4422(17)30157-6_bib23) 2012; 18 Asai (10.1016/S1474-4422(17)30157-6_bib99) 2015; 18 Spinelli (10.1016/S1474-4422(17)30157-6_bib22) 2017; 81 Clavaguera (10.1016/S1474-4422(17)30157-6_bib37) 2013; 110 |
| References_xml | – volume: 9 start-page: eeag0481 year: 2017 ident: bib89 article-title: Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy publication-title: Sci Transl Med – volume: 76 start-page: 1006 year: 2011 end-page: 1014 ident: bib31 article-title: Classification of primary progressive aphasia and its variants publication-title: Neurology – volume: 21 start-page: 394 year: 2015 end-page: 402 ident: bib97 article-title: Tau immunotherapy for Alzheimer's disease publication-title: Trends Mol Med – volume: 2 start-page: 278 year: 2015 end-page: 288 ident: bib50 article-title: Anti-tau antibody reduces insoluble tau and decreases brain atrophy publication-title: Ann Clin Transl Neurol – volume: 8 start-page: 270 year: 2009 end-page: 279 ident: bib1 article-title: Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges publication-title: Lancet Neurol – volume: 9 start-page: 149 year: 2010 end-page: 158 ident: bib61 article-title: Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis publication-title: Lancet Neurol – volume: 21 start-page: 3500 year: 2012 end-page: 3512 ident: bib41 article-title: Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases publication-title: Hum Mol Genet – volume: 80 start-page: 1347 year: 2013 end-page: 1358 ident: bib11 article-title: Biomarker modeling of Alzheimer's disease publication-title: Neuron – year: 2016 ident: bib40 article-title: Molecular genetics of neurodegenerative dementias publication-title: Cold Spring Harb Perspect Biol – volume: 8 start-page: 393 year: 2012 end-page: 399 ident: bib88 article-title: Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation publication-title: Nat Chem Biol – volume: 33 start-page: 2817 year: 2012 end-page: 2826 ident: bib57 article-title: Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism publication-title: Neurobiol Aging – volume: 6 start-page: e00557 year: 2016 ident: bib6 article-title: Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade publication-title: Brain Behav – volume: 25 start-page: 357 year: 2010 end-page: 362 ident: bib17 article-title: What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? publication-title: Mov Disord – volume: 132 start-page: 502 year: 2009 end-page: 510 ident: bib75 article-title: Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy publication-title: Brain – volume: 30 start-page: 1600 year: 2015 end-page: 1611 ident: bib12 article-title: MDS research criteria for prodromal Parkinson's disease publication-title: Mov Disord – year: 2017 ident: bib10 article-title: Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria publication-title: Mov Disord – volume: 20 start-page: 525 year: 2014 end-page: 529 ident: bib34 article-title: Concomitant pathologies among a spectrum of parkinsonian disorders publication-title: Parkinsonism Relat Disord – volume: 27 start-page: 1754 year: 2012 end-page: 1762 ident: bib47 article-title: Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy publication-title: Mov Disord – volume: 10 start-page: 333 year: 1964 end-page: 359 ident: bib2 article-title: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia publication-title: Arch Neurol – year: 2017 ident: bib91 article-title: Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial publication-title: J Neurol Neurosurg Psychiatry – volume: 28 start-page: 504 year: 2013 end-page: 509 ident: bib16 article-title: Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy publication-title: Mov Disord – volume: 82 start-page: 1271 year: 2014 end-page: 1288 ident: bib38 article-title: Distinct tau prion strains propagate in cells and mice and define different tauopathies publication-title: Neuron – volume: 112 start-page: 3086 year: 2014 end-page: 3094 ident: bib66 article-title: The binaural masking level difference: cortical correlates persist despite severe brain stem atrophy in progressive supranuclear palsy publication-title: J Neurophysiol – volume: 86 start-page: 1240 year: 2015 end-page: 1247 ident: bib72 article-title: A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes publication-title: J Neurol Neurosurg Psychiatry – volume: 21 start-page: 101 year: 2015 end-page: 105 ident: bib43 article-title: Three sib-pairs of autopsy-confirmed progressive supranuclear palsy publication-title: Parkinsonism Relat Disord – volume: 29 start-page: 1758 year: 2014 end-page: 1766 ident: bib15 article-title: The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases publication-title: Mov Disord – volume: 18 start-page: 478 year: 2012 end-page: 488 ident: bib23 article-title: Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia publication-title: Neurocase – volume: 32 start-page: 108 year: 2017 end-page: 114 ident: bib65 article-title: Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy publication-title: Mov Disord – volume: 91 start-page: 56 year: 2016 end-page: 66 ident: bib71 article-title: Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases publication-title: Neuron – volume: 23 start-page: 942 year: 2008 end-page: 949 ident: bib90 article-title: Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial publication-title: Mov Disord – volume: 73 start-page: 733 year: 2016 end-page: 742 ident: bib21 article-title: Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration publication-title: JAMA Neurol – volume: 134 start-page: 2456 year: 2011 end-page: 2477 ident: bib32 article-title: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia publication-title: Brain – volume: 88 start-page: 930 year: 2017 end-page: 937 ident: bib73 article-title: Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder publication-title: Neurology – volume: 87 start-page: 1266 year: 2016 end-page: 1273 ident: bib54 article-title: MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism publication-title: Neurology – volume: 18 start-page: 1584 year: 2015 end-page: 1593 ident: bib99 article-title: Depletion of microglia and inhibition of exosome synthesis halt tau propagation publication-title: Nat Neurosci – volume: 87 start-page: 709 year: 2016 end-page: 717 ident: bib59 article-title: Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes publication-title: Neurology – volume: 85 start-page: 1293 year: 2015 end-page: 1300 ident: bib8 article-title: A geographical cluster of progressive supranuclear palsy in northern France publication-title: Neurology – volume: 55 start-page: 97 year: 1996 end-page: 105 ident: bib24 article-title: Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders publication-title: J Neuropathol Exp Neurol – volume: 90 start-page: 941 year: 2016 end-page: 947 ident: bib44 article-title: Increased 4R-tau induces pathological changes in a human-tau mouse model publication-title: Neuron – volume: 87 start-page: 963 year: 2015 end-page: 975 ident: bib45 article-title: Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis publication-title: Neuron – volume: 12 start-page: 1051 year: 2016 end-page: 1065 ident: bib84 article-title: Therapeutic strategies for the treatment of tauopathies: hopes and challenges publication-title: Alzheimers Dement – volume: 82 start-page: 266 year: 2015 end-page: 273 ident: bib14 article-title: Early stage of progressive supranuclear palsy: a neuropathological study of 324 consecutive autopsy cases publication-title: J Nippon Med Sch – volume: 140 start-page: 764 year: 2017 end-page: 780 ident: bib80 article-title: Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies publication-title: Brain – volume: 3 start-page: 216 year: 2016 end-page: 225 ident: bib74 article-title: Plasma neurofilament light chain predicts progression in progressive supranuclear palsy publication-title: Ann Clin Transl Neurol – volume: 77 start-page: 1042 year: 2011 end-page: 1047 ident: bib52 article-title: MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study publication-title: Neurology – volume: 78 start-page: 787 year: 2015 end-page: 800 ident: bib62 article-title: Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue publication-title: Ann Neurol – volume: 86 start-page: 1736 year: 2016 end-page: 1743 ident: bib5 article-title: Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes publication-title: Neurology – volume: 74 start-page: 850 year: 2015 end-page: 857 ident: bib46 article-title: Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase publication-title: J Neuropathol Exp Neurol – volume: 132 start-page: 156 year: 2009 end-page: 171 ident: bib93 article-title: Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study publication-title: Brain – volume: 69 start-page: 1445 year: 2012 end-page: 1452 ident: bib68 article-title: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders publication-title: Arch Neurol – volume: 330 start-page: 198 year: 2010 ident: bib98 article-title: Tau reduction prevents Abeta-induced defects in axonal transport publication-title: Science – volume: 22 start-page: 50 year: 2016 end-page: 56 ident: bib77 article-title: Rest-activity rhythm disruption in progressive supranuclear palsy publication-title: Sleep Med – volume: 31 start-page: 644 year: 2016 end-page: 652 ident: bib9 article-title: Environmental and occupational risk factors for progressive supranuclear palsy: case-control study publication-title: Mov Disord – volume: 32 start-page: 134 year: 2017 end-page: 140 ident: bib63 article-title: Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy publication-title: Mov Disord – volume: 133 start-page: 2045 year: 2010 end-page: 2057 ident: bib19 article-title: Does corticobasal degeneration exist? A clinicopathological re-evaluation publication-title: Brain – volume: 34 start-page: 225 year: 2014 end-page: 234 ident: bib92 article-title: Clinical trials: past, current, and future for atypical Parkinsonian syndromes publication-title: Semin Neurol – volume: 23 start-page: 394 year: 2010 end-page: 400 ident: bib35 article-title: Neuropathology of variants of progressive supranuclear palsy publication-title: Curr Opin Neurol – volume: 29 start-page: 470 year: 2014 end-page: 478 ident: bib94 article-title: A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy publication-title: Mov Disord – volume: 263 start-page: 2419 year: 2016 end-page: 2423 ident: bib18 article-title: The clinical spectrum and natural history of pure akinesia with gait freezing publication-title: J Neurol – volume: 135 start-page: 1141 year: 2012 end-page: 1153 ident: bib78 article-title: Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease publication-title: Brain – volume: 36 start-page: 1316 year: 2016 end-page: 1323 ident: bib101 article-title: Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration publication-title: J Neurosci – volume: 20 start-page: 1417 year: 2013 end-page: 1422 ident: bib51 article-title: Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology publication-title: Eur J Neurol – volume: 21 start-page: 1154 year: 2015 end-page: 1162 ident: bib49 article-title: Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits publication-title: Nat Med – volume: 75 start-page: 116 year: 2014 end-page: 126 ident: bib69 article-title: Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration publication-title: Ann Neurol – volume: 80 start-page: 496 year: 2013 end-page: 503 ident: bib30 article-title: Criteria for the diagnosis of corticobasal degeneration publication-title: Neurology – volume: 36 start-page: 693 year: 2015 end-page: 709 ident: bib86 article-title: Human secreted tau increases amyloid-beta production publication-title: Neurobiol Aging – volume: 13 start-page: 676 year: 2014 end-page: 685 ident: bib70 article-title: Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial publication-title: Lancet Neurol – volume: 11 start-page: e0157218 year: 2016 ident: bib56 article-title: Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study publication-title: PLoS One – volume: 20 start-page: 659 year: 2014 end-page: 663 ident: bib87 article-title: Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice publication-title: Nat Med – volume: 86 start-page: 244 year: 2015 end-page: 250 ident: bib67 article-title: Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy publication-title: J Neurol Neurosurg Psychiatry – volume: 139 start-page: 495 year: 2016 end-page: 508 ident: bib58 article-title: Free-water imaging in Parkinson's disease and atypical parkinsonism publication-title: Brain – volume: 29 start-page: 280 year: 2008 end-page: 289 ident: bib48 article-title: Voxel-based morphometry in autopsy proven PSP and CBD publication-title: Neurobiol Aging – volume: 69 start-page: 509 year: 2012 end-page: 517 ident: bib29 article-title: Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease publication-title: Arch Neurol – volume: 24 start-page: 1312 year: 2009 end-page: 1318 ident: bib33 article-title: Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study publication-title: Mov Disord – volume: 3 start-page: e266 year: 2016 ident: bib83 article-title: CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial publication-title: Neurol Neuroimmunol Neuroinflamm – volume: 1 start-page: 147 year: 2010 ident: bib81 article-title: The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis publication-title: Front Neurol – volume: 43 start-page: 699 year: 2011 end-page: 705 ident: bib4 article-title: Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy publication-title: Nat Genet – volume: 126 start-page: 365 year: 2013 end-page: 384 ident: bib26 article-title: Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series publication-title: Acta Neuropathol – volume: 80 start-page: 402 year: 2013 end-page: 414 ident: bib95 article-title: Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo publication-title: Neuron – volume: 43 start-page: 1139 year: 2016 end-page: 1150 ident: bib79 article-title: Tau imaging in neurodegenerative diseases publication-title: Eur J Nucl Med Mol Imaging – volume: 80 start-page: 1856 year: 2013 end-page: 1861 ident: bib53 article-title: The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy publication-title: Neurology – volume: 87 start-page: 2016 year: 2016 end-page: 2025 ident: bib55 article-title: Progression of brain atrophy in PSP and CBS over 6 months and 1 year publication-title: Neurology – volume: 73 start-page: 244 year: 2014 end-page: 252 ident: bib13 article-title: Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers publication-title: J Neuropathol Exp Neurol – volume: 31 start-page: 653 year: 2016 end-page: 662 ident: bib25 article-title: Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C publication-title: Mov Disord – volume: 9 start-page: 3 year: 2016 end-page: 13 ident: bib27 article-title: Clinical approach to progressive supranuclear palsy publication-title: J Mov Disord – volume: 388 start-page: 2873 year: 2016 end-page: 2884 ident: bib85 article-title: Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial publication-title: Lancet – volume: 261 start-page: 710 year: 2014 end-page: 716 ident: bib60 article-title: FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants publication-title: J Neurol – volume: 32 start-page: 124 year: 2017 end-page: 133 ident: bib64 article-title: [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy publication-title: Movement Disord – volume: 47 start-page: 1 year: 1996 end-page: 9 ident: bib28 article-title: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop publication-title: Neurology – volume: 137 start-page: 2783 year: 2014 end-page: 2795 ident: bib20 article-title: The evolution of primary progressive apraxia of speech publication-title: Brain – volume: 81 start-page: 430 year: 2017 end-page: 443 ident: bib22 article-title: Typical and atypical pathology in primary progressive aphasia variants publication-title: Ann Neurol – volume: 73 start-page: 603 year: 2013 end-page: 616 ident: bib39 article-title: Intrinsic connectivity network disruption in progressive supranuclear palsy publication-title: Ann Neurol – volume: 121 start-page: 41 year: 2014 end-page: 47 ident: bib76 article-title: Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study publication-title: J Neural Transm – volume: 18 start-page: 42 year: 2016 ident: bib3 article-title: Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options publication-title: Curr Treat Options Neurol – volume: 110 start-page: 9535 year: 2013 end-page: 9540 ident: bib37 article-title: Brain homogenates from human tauopathies induce tau inclusions in mouse brain publication-title: Proc Natl Acad Sci USA – volume: 133 start-page: 809 year: 2017 end-page: 823 ident: bib7 article-title: Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series publication-title: Acta Neuropathol – volume: 523 start-page: 431 year: 2015 end-page: 436 ident: bib96 article-title: Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy publication-title: Nature – volume: 40 start-page: 149 year: 2014 end-page: 163 ident: bib36 article-title: Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant publication-title: Neuropathol Appl Neurobiol – volume: 73 start-page: 98 year: 2009 end-page: 105 ident: bib42 article-title: Familial aggregation of parkinsonism in progressive supranuclear palsy publication-title: Neurology – volume: 68 start-page: 19 year: 2010 end-page: 31 ident: bib100 article-title: Regulation of tau pathology by the microglial fractalkine receptor publication-title: Neuron – volume: 12 start-page: e0170927 year: 2017 ident: bib82 article-title: Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments publication-title: PLoS One – volume: 30 start-page: 9973 year: 2010 end-page: 9983 ident: bib102 article-title: Cell-mediated neuroprotection in a mouse model of human tauopathy publication-title: J Neurosci – volume: 23 start-page: 942 year: 2008 ident: 10.1016/S1474-4422(17)30157-6_bib90 article-title: Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial publication-title: Mov Disord doi: 10.1002/mds.22023 – volume: 88 start-page: 930 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib73 article-title: Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder publication-title: Neurology doi: 10.1212/WNL.0000000000003680 – volume: 85 start-page: 1293 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib8 article-title: A geographical cluster of progressive supranuclear palsy in northern France publication-title: Neurology doi: 10.1212/WNL.0000000000001997 – volume: 12 start-page: e0170927 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib82 article-title: Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments publication-title: PLoS One doi: 10.1371/journal.pone.0170927 – volume: 8 start-page: 270 year: 2009 ident: 10.1016/S1474-4422(17)30157-6_bib1 article-title: Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70042-0 – volume: 69 start-page: 1445 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib68 article-title: Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders publication-title: Arch Neurol doi: 10.1001/archneurol.2012.1654 – volume: 82 start-page: 266 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib14 article-title: Early stage of progressive supranuclear palsy: a neuropathological study of 324 consecutive autopsy cases publication-title: J Nippon Med Sch doi: 10.1272/jnms.82.266 – volume: 33 start-page: 2817 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib57 article-title: Diffusion tensor MRI contributes to differentiate Richardson's syndrome from PSP-parkinsonism publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2012.02.002 – volume: 9 start-page: 149 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib61 article-title: Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70002-8 – volume: 388 start-page: 2873 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib85 article-title: Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)31275-2 – volume: 69 start-page: 509 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib29 article-title: Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease publication-title: Arch Neurol doi: 10.1001/archneurol.2011.1021 – volume: 18 start-page: 1584 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib99 article-title: Depletion of microglia and inhibition of exosome synthesis halt tau propagation publication-title: Nat Neurosci doi: 10.1038/nn.4132 – volume: 31 start-page: 644 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib9 article-title: Environmental and occupational risk factors for progressive supranuclear palsy: case-control study publication-title: Mov Disord doi: 10.1002/mds.26512 – volume: 47 start-page: 1 year: 1996 ident: 10.1016/S1474-4422(17)30157-6_bib28 article-title: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop publication-title: Neurology doi: 10.1212/WNL.47.1.1 – volume: 110 start-page: 9535 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib37 article-title: Brain homogenates from human tauopathies induce tau inclusions in mouse brain publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.1301175110 – volume: 21 start-page: 101 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib43 article-title: Three sib-pairs of autopsy-confirmed progressive supranuclear palsy publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2014.10.028 – year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib40 article-title: Molecular genetics of neurodegenerative dementias publication-title: Cold Spring Harb Perspect Biol – volume: 87 start-page: 1266 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib54 article-title: MR parkinsonism index predicts vertical supranuclear gaze palsy in patients with PSP-parkinsonism publication-title: Neurology doi: 10.1212/WNL.0000000000003125 – volume: 36 start-page: 1316 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib101 article-title: Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration publication-title: J Neurosci doi: 10.1523/JNEUROSCI.2336-15.2016 – volume: 80 start-page: 1347 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib11 article-title: Biomarker modeling of Alzheimer's disease publication-title: Neuron doi: 10.1016/j.neuron.2013.12.003 – volume: 21 start-page: 3500 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib41 article-title: Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases publication-title: Hum Mol Genet doi: 10.1093/hmg/dds161 – volume: 73 start-page: 603 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib39 article-title: Intrinsic connectivity network disruption in progressive supranuclear palsy publication-title: Ann Neurol doi: 10.1002/ana.23844 – volume: 25 start-page: 357 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib17 article-title: What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)? publication-title: Mov Disord doi: 10.1002/mds.22977 – volume: 80 start-page: 1856 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib53 article-title: The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy publication-title: Neurology doi: 10.1212/WNL.0b013e318292a2d2 – volume: 21 start-page: 394 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib97 article-title: Tau immunotherapy for Alzheimer's disease publication-title: Trends Mol Med doi: 10.1016/j.molmed.2015.03.003 – volume: 36 start-page: 693 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib86 article-title: Human secreted tau increases amyloid-beta production publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2014.09.007 – volume: 73 start-page: 98 year: 2009 ident: 10.1016/S1474-4422(17)30157-6_bib42 article-title: Familial aggregation of parkinsonism in progressive supranuclear palsy publication-title: Neurology doi: 10.1212/WNL.0b013e3181a92bcc – volume: 31 start-page: 653 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib25 article-title: Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C publication-title: Mov Disord doi: 10.1002/mds.26499 – volume: 91 start-page: 56 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib71 article-title: Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases publication-title: Neuron doi: 10.1016/j.neuron.2016.05.018 – volume: 134 start-page: 2456 year: 2011 ident: 10.1016/S1474-4422(17)30157-6_bib32 article-title: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia publication-title: Brain doi: 10.1093/brain/awr179 – volume: 87 start-page: 2016 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib55 article-title: Progression of brain atrophy in PSP and CBS over 6 months and 1 year publication-title: Neurology doi: 10.1212/WNL.0000000000003305 – volume: 77 start-page: 1042 year: 2011 ident: 10.1016/S1474-4422(17)30157-6_bib52 article-title: MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study publication-title: Neurology doi: 10.1212/WNL.0b013e31822e55d0 – volume: 29 start-page: 470 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib94 article-title: A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy publication-title: Mov Disord doi: 10.1002/mds.25824 – volume: 1 start-page: 147 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib81 article-title: The disturbance of gaze in progressive supranuclear palsy: implications for pathogenesis publication-title: Front Neurol doi: 10.3389/fneur.2010.00147 – volume: 43 start-page: 699 year: 2011 ident: 10.1016/S1474-4422(17)30157-6_bib4 article-title: Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy publication-title: Nat Genet doi: 10.1038/ng.859 – volume: 30 start-page: 9973 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib102 article-title: Cell-mediated neuroprotection in a mouse model of human tauopathy publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0834-10.2010 – volume: 132 start-page: 156 year: 2009 ident: 10.1016/S1474-4422(17)30157-6_bib93 article-title: Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study publication-title: Brain doi: 10.1093/brain/awn291 – volume: 86 start-page: 1736 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib5 article-title: Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes publication-title: Neurology doi: 10.1212/WNL.0000000000002638 – volume: 24 start-page: 1312 year: 2009 ident: 10.1016/S1474-4422(17)30157-6_bib33 article-title: Cerebellar involvement in progressive supranuclear palsy: a clinicopathological study publication-title: Mov Disord doi: 10.1002/mds.22583 – volume: 34 start-page: 225 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib92 article-title: Clinical trials: past, current, and future for atypical Parkinsonian syndromes publication-title: Semin Neurol doi: 10.1055/s-0034-1381739 – volume: 32 start-page: 108 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib65 article-title: Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy publication-title: Mov Disord doi: 10.1002/mds.26813 – volume: 86 start-page: 1240 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib72 article-title: A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2014-309562 – volume: 133 start-page: 809 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib7 article-title: Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series publication-title: Acta Neuropathol doi: 10.1007/s00401-016-1665-7 – volume: 135 start-page: 1141 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib78 article-title: Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease publication-title: Brain doi: 10.1093/brain/aws038 – volume: 74 start-page: 850 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib46 article-title: Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0000000000000224 – volume: 523 start-page: 431 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib96 article-title: Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy publication-title: Nature doi: 10.1038/nature14658 – volume: 55 start-page: 97 year: 1996 ident: 10.1016/S1474-4422(17)30157-6_bib24 article-title: Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders publication-title: J Neuropathol Exp Neurol doi: 10.1097/00005072-199601000-00010 – volume: 78 start-page: 787 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib62 article-title: Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue publication-title: Ann Neurol doi: 10.1002/ana.24517 – volume: 13 start-page: 676 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib70 article-title: Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70088-2 – volume: 29 start-page: 1758 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib15 article-title: The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases publication-title: Mov Disord doi: 10.1002/mds.26054 – volume: 75 start-page: 116 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib69 article-title: Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration publication-title: Ann Neurol doi: 10.1002/ana.24052 – volume: 30 start-page: 1600 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib12 article-title: MDS research criteria for prodromal Parkinson's disease publication-title: Mov Disord doi: 10.1002/mds.26431 – volume: 20 start-page: 1417 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib51 article-title: Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology publication-title: Eur J Neurol doi: 10.1111/ene.12212 – volume: 18 start-page: 478 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib23 article-title: Autopsy-proven progressive supranuclear palsy presenting as behavioral variant frontotemporal dementia publication-title: Neurocase doi: 10.1080/13554794.2011.627345 – volume: 73 start-page: 244 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib13 article-title: Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers publication-title: J Neuropathol Exp Neurol doi: 10.1097/NEN.0000000000000046 – volume: 12 start-page: 1051 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib84 article-title: Therapeutic strategies for the treatment of tauopathies: hopes and challenges publication-title: Alzheimers Dement doi: 10.1016/j.jalz.2016.06.006 – volume: 29 start-page: 280 year: 2008 ident: 10.1016/S1474-4422(17)30157-6_bib48 article-title: Voxel-based morphometry in autopsy proven PSP and CBD publication-title: Neurobiol Aging doi: 10.1016/j.neurobiolaging.2006.09.019 – volume: 10 start-page: 333 year: 1964 ident: 10.1016/S1474-4422(17)30157-6_bib2 article-title: Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia publication-title: Arch Neurol doi: 10.1001/archneur.1964.00460160003001 – volume: 22 start-page: 50 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib77 article-title: Rest-activity rhythm disruption in progressive supranuclear palsy publication-title: Sleep Med doi: 10.1016/j.sleep.2016.05.002 – volume: 82 start-page: 1271 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib38 article-title: Distinct tau prion strains propagate in cells and mice and define different tauopathies publication-title: Neuron doi: 10.1016/j.neuron.2014.04.047 – volume: 9 start-page: 3 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib27 article-title: Clinical approach to progressive supranuclear palsy publication-title: J Mov Disord doi: 10.14802/jmd.15060 – volume: 11 start-page: e0157218 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib56 article-title: Progression of microstructural degeneration in progressive supranuclear palsy and corticobasal syndrome: a longitudinal diffusion tensor imaging study publication-title: PLoS One doi: 10.1371/journal.pone.0157218 – volume: 139 start-page: 495 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib58 article-title: Free-water imaging in Parkinson's disease and atypical parkinsonism publication-title: Brain doi: 10.1093/brain/awv361 – volume: 137 start-page: 2783 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib20 article-title: The evolution of primary progressive apraxia of speech publication-title: Brain doi: 10.1093/brain/awu223 – volume: 121 start-page: 41 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib76 article-title: Retinal single-layer analysis in Parkinsonian syndromes: an optical coherence tomography study publication-title: J Neural Transm doi: 10.1007/s00702-013-1072-3 – volume: 43 start-page: 1139 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib79 article-title: Tau imaging in neurodegenerative diseases publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-015-3231-2 – volume: 126 start-page: 365 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib26 article-title: Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series publication-title: Acta Neuropathol doi: 10.1007/s00401-013-1157-y – volume: 68 start-page: 19 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib100 article-title: Regulation of tau pathology by the microglial fractalkine receptor publication-title: Neuron doi: 10.1016/j.neuron.2010.08.023 – volume: 6 start-page: e00557 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib6 article-title: Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade publication-title: Brain Behav doi: 10.1002/brb3.557 – volume: 263 start-page: 2419 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib18 article-title: The clinical spectrum and natural history of pure akinesia with gait freezing publication-title: J Neurol doi: 10.1007/s00415-016-8278-x – volume: 81 start-page: 430 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib22 article-title: Typical and atypical pathology in primary progressive aphasia variants publication-title: Ann Neurol doi: 10.1002/ana.24885 – volume: 27 start-page: 1754 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib47 article-title: Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy publication-title: Mov Disord doi: 10.1002/mds.24968 – volume: 40 start-page: 149 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib36 article-title: Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant publication-title: Neuropathol Appl Neurobiol doi: 10.1111/nan.12037 – volume: 9 start-page: eeag0481 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib89 article-title: Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aag0481 – volume: 132 start-page: 502 year: 2009 ident: 10.1016/S1474-4422(17)30157-6_bib75 article-title: Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy publication-title: Brain doi: 10.1093/brain/awn317 – volume: 90 start-page: 941 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib44 article-title: Increased 4R-tau induces pathological changes in a human-tau mouse model publication-title: Neuron doi: 10.1016/j.neuron.2016.04.042 – volume: 87 start-page: 709 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib59 article-title: Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes publication-title: Neurology doi: 10.1212/WNL.0000000000002985 – volume: 23 start-page: 394 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib35 article-title: Neuropathology of variants of progressive supranuclear palsy publication-title: Curr Opin Neurol doi: 10.1097/WCO.0b013e32833be924 – volume: 3 start-page: e266 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib83 article-title: CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000266 – volume: 80 start-page: 496 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib30 article-title: Criteria for the diagnosis of corticobasal degeneration publication-title: Neurology doi: 10.1212/WNL.0b013e31827f0fd1 – volume: 32 start-page: 134 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib63 article-title: Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy publication-title: Mov Disord doi: 10.1002/mds.26844 – volume: 87 start-page: 963 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib45 article-title: Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis publication-title: Neuron doi: 10.1016/j.neuron.2015.08.020 – volume: 3 start-page: 216 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib74 article-title: Plasma neurofilament light chain predicts progression in progressive supranuclear palsy publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.290 – volume: 18 start-page: 42 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib3 article-title: Progressive supranuclear palsy and corticobasal degeneration: pathophysiology and treatment options publication-title: Curr Treat Options Neurol doi: 10.1007/s11940-016-0422-5 – volume: 80 start-page: 402 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib95 article-title: Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo publication-title: Neuron doi: 10.1016/j.neuron.2013.07.046 – volume: 112 start-page: 3086 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib66 article-title: The binaural masking level difference: cortical correlates persist despite severe brain stem atrophy in progressive supranuclear palsy publication-title: J Neurophysiol doi: 10.1152/jn.00062.2014 – volume: 73 start-page: 733 year: 2016 ident: 10.1016/S1474-4422(17)30157-6_bib21 article-title: Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2016.0412 – volume: 21 start-page: 1154 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib49 article-title: Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits publication-title: Nat Med doi: 10.1038/nm.3951 – volume: 261 start-page: 710 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib60 article-title: FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants publication-title: J Neurol doi: 10.1007/s00415-014-7256-4 – volume: 20 start-page: 659 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib87 article-title: Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice publication-title: Nat Med doi: 10.1038/nm.3569 – volume: 2 start-page: 278 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib50 article-title: Anti-tau antibody reduces insoluble tau and decreases brain atrophy publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.176 – year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib10 article-title: Clinical diagnosis of progressive supranuclear palsy: The Movement Disorder Society criteria publication-title: Mov Disord doi: 10.1002/mds.26987 – year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib91 article-title: Peduncolopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2016-315192 – volume: 86 start-page: 244 year: 2015 ident: 10.1016/S1474-4422(17)30157-6_bib67 article-title: Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2014-308004 – volume: 20 start-page: 525 year: 2014 ident: 10.1016/S1474-4422(17)30157-6_bib34 article-title: Concomitant pathologies among a spectrum of parkinsonian disorders publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2014.02.012 – volume: 32 start-page: 124 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib64 article-title: [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy publication-title: Movement Disord doi: 10.1002/mds.26834 – volume: 133 start-page: 2045 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib19 article-title: Does corticobasal degeneration exist? A clinicopathological re-evaluation publication-title: Brain doi: 10.1093/brain/awq123 – volume: 76 start-page: 1006 year: 2011 ident: 10.1016/S1474-4422(17)30157-6_bib31 article-title: Classification of primary progressive aphasia and its variants publication-title: Neurology doi: 10.1212/WNL.0b013e31821103e6 – volume: 28 start-page: 504 year: 2013 ident: 10.1016/S1474-4422(17)30157-6_bib16 article-title: Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy publication-title: Mov Disord doi: 10.1002/mds.25327 – volume: 140 start-page: 764 year: 2017 ident: 10.1016/S1474-4422(17)30157-6_bib80 article-title: Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies publication-title: Brain – volume: 330 start-page: 198 year: 2010 ident: 10.1016/S1474-4422(17)30157-6_bib98 article-title: Tau reduction prevents Abeta-induced defects in axonal transport publication-title: Science doi: 10.1126/science.1194653 – volume: 8 start-page: 393 year: 2012 ident: 10.1016/S1474-4422(17)30157-6_bib88 article-title: Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation publication-title: Nat Chem Biol doi: 10.1038/nchembio.797 |
| SSID | ssj0021481 |
| Score | 2.6465163 |
| SecondaryResourceType | review_article |
| Snippet | Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural... Summary Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 552 |
| SubjectTerms | Alzheimer's disease Basal ganglia Biomarkers Brain diseases Brain research Central nervous system diseases Clinical trials Encephalopathy Humans Medical diagnosis Motor task performance Movement disorders Neurodegeneration Neurodegenerative diseases Neurology Neuropathology Paralysis Pathology Progressive supranuclear palsy Supranuclear Palsy, Progressive - diagnosis Supranuclear Palsy, Progressive - therapy Tau protein Therapeutic applications |
| Title | Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1474442217301576 https://www.clinicalkey.es/playcontent/1-s2.0-S1474442217301576 https://dx.doi.org/10.1016/S1474-4422(17)30157-6 https://www.ncbi.nlm.nih.gov/pubmed/28653647 https://www.proquest.com/docview/1911184882 https://www.proquest.com/docview/1914291910 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dS9xAEB9aBelL0dbq-cUKfbDgapLbZPd8ESuKCIrYCve2ZJNdEEvuvNwV-t87s9nkfNDqyz3k8ktgdnbmN9n5APie2jx2yAy4taniwsUZxzDCcZeXyjijBsa3L766zi7uxOUwHYYPbnVIq2xtojfU5aigb-SHMe1KheqWHI8fOU2NotPVMELjIyxS6zJK6ZLDecCFVN8HXEIKLkSSzCt4Dn91F_di-QO1PJU8e803vcY9vQ86X4bPgTyyk2a1V-CDrb7A0lU4Hv8KDyfNiX7N7ivmM68oyfWvZfVsjD6JWhfnEzZGjft3xJBPs7JJtMPHMbQe1LY532dUkU9JO5N6n-VVyZ6VaLG2BbmtV-Hu_Oz36QUP0xR4gTHglLtUSQxvpIoSq9LIWuQmzpg4d5GRMhdogY1M0aEXCS6RwzBMlRkGzgqtuTEq63-DhWpU2XVgUVkOCmfKAumSsKlRkVMuw7uSQWT6A9MD0cpRF6HVOE28-KO7nDISvybx61hqL36d9eCgg42bXhtvAbJ2kXRbSIqmT6M3eAsoXwLaOmzgWse6TnTUoAkcSw9FpOqQgaM03OM9L91q9UjP39OpdQ92u79xi9O5TV7Z0czfg6wBf6MerDX618mHCotpBMDG_x--CZ8S4iM-z3gLFqaTmd1GNjU1O37L7MDiz7Prm9snIyEZeA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcEG8WChgJJJDqNvE6sRcJoQKttrS7QtBKvZk4saWqKLtsdkH9U_xGZpxHOVDKpZcckowTTebxTTwPgOeJy2KPyIA7l2gufZxyDCM891mhrbd6aEP74vEkHR3Kj0fJ0Qr8amthKK2ytYnBUBfTnP6Rb8aklRrFTbydfec0NYp2V9sRGrVY7LnTnxiyVW92P-D3fSHEzvbB-xFvpgrwHGOhBfeJVgjzlY6E00nkHPpob22c-cgqlUm0RFYl6Nhyga_qMRzRRYoBpEarZq1OB7juFViVAwxlerD6bnvy6XMX4mFwEUI8qSSXUoizmqHNL93Jl7F6hXqVKJ6e5w3PQ7vB6-3chBsNXGVbtXzdghVX3oar42ZD_g6cbNU5BBU7LlnI9aK02h-OVcsZekFqlpzN2Qxl_PQ1QwTPijq1D5djaK-oUXS2zqgHAKUJzat1lpUF-6MojLVNz111Fw4vhdP3oFdOS_cAWFQUw9zbIkeAJl1ideS1T_EuMYzsYGj7IFs-mrxpbk4zNr6ZLouN2G-I_SZWJrDfpH3Y6MhmdXePiwjS9iOZtnQVja1B_3MRofoboasak1GZ2FTCRDU1EccqkCKl7igbVFSjnf956ForR-bsOZ0i9eFZdxmNCu0UZaWbLsM9iFPwGPXhfi1_HX-olJmGDjz89-JP4droYLxv9ncne4_guiA0FLKc16C3mC_dY8RyC_ukUSAGXy9bZ38DZjBV3w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qheKL-O1p1RUUFLpedm-T3RNEivVorS2CFu5tzSa7IEruvNwp_df865zZfJwP1vrSlzwkmU2YzMdvsvMB8CT1uQiIDLj3qeEqiIxjGBF4yEvjgjNjF9sXHx1n-yfq3TSdbsCvrhaG0io7mxgNdTkr6B_5UJBWGhQ3OQxtWsSHvcnr-XdOE6Rop7Ubp9GIyKE__YnhW_3qYA-_9VMpJ28_vdnn7YQBXmBctOQhNRohvzaJ9CZNvEd_HZwTeUic1rlCq-R0ik6ukPjaAUMTU2YYTBq0cM6ZbITrXoLLepQK0jE9XQd7GGbEYE9pxZWScl09NPzYn3wm9HPUsFTz7Cy_eBbujf5vcg2utsCV7TaSdh02fHUDto7arfmb8HW3ySao2ZeKxawvSrD94Vm9mqM_pLbJ-YLNUdpPXzLE8qxskvxwOYaWi1pG5zuMugFQwtCi3mF5VbI_ysNY1_7c17fg5EL4fBs2q1nl7wJLynJcBFcWCNWUT51JggkZ3iXHiRuN3QBUx0dbtG3OadrGN9vnsxH7LbHfCm0j-202gBc92bzp83EeQdZ9JNsVsaLZteiJziPUfyP0dWs8aitsLW3SUBOx0JEUKU1P2eKjBvf8z0O3Ozmy6-f0KjWAx_1lNC-0Z5RXfraK9yBiwWMygDuN_PX8oaJmGj9w79-LP4It1FT7_uD48D5ckQSLYrrzNmwuFyv_AEHd0j2M2sPg80Wr62_Nh1iv |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+progressive+supranuclear+palsy%3A+new+diagnostic+criteria%2C+biomarkers%2C+and+therapeutic+approaches&rft.jtitle=Lancet+neurology&rft.au=Boxer%2C+Adam+L&rft.au=Yu%2C+Jin-Tai&rft.au=Golbe%2C+Lawrence+I&rft.au=Litvan%2C+Irene&rft.date=2017-07-01&rft.issn=1474-4465&rft.eissn=1474-4465&rft.volume=16&rft.issue=7&rft.spage=552&rft_id=info:doi/10.1016%2FS1474-4422%2817%2930157-6&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14744422%2FS1474442217X00069%2Fcov150h.gif |